Mesenchymal stromal cells for systemic sclerosis treatment - MICMAC : Microenvironment, Cell Differentiation, Immunology and Cancer Accéder directement au contenu
Article Dans Une Revue Autoimmunity Reviews Année : 2021

Mesenchymal stromal cells for systemic sclerosis treatment

Résumé

Systemic sclerosis (SSc) is a rare chronic autoimmune disease characterized by vasculopathy, dysregulation of innate and adaptive immune responses, and progressive fibrosis. SSc remains an orphan disease, with high morbity and mortality in SSc patients. The mesenchymal stromal cells (MSC) demonstrate in vitro and in vivo pro-angiogenic, immuno-suppressive, and anti-fibrotic properties and appear as a promising stem cell therapy type, that may target the key pathological features of SSc disease. This review aims to summarize acquired knowledge in the field of :1) MSC definition and in vitro and in vivo functional properties, which vary according to the donor type (allogeneic or autologous), the tissue sources (bone marrow, adipose tissue or umbilical cord) or inflammatory micro-environment in the recipient; 2) preclinical studies in various SSc animal models , which showed reduction in skin and lung fibrosis after MSC infusion; 3) first clinical trials in human, with safety and early efficacy results reported in SSc patients or currently tested in several ongoing clinical trials.
Fichier principal
Vignette du fichier
Farge et al. - 2021 - Mesenchymal stromal cells for systemic sclerosis t.pdf (2.06 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03163978 , version 1 (19-05-2021)

Identifiants

Citer

Dominique Farge, Séverine Loisel, Pauline Lansiaux, Karin Tarte. Mesenchymal stromal cells for systemic sclerosis treatment. Autoimmunity Reviews, 2021, 20 (3), pp.102755. ⟨10.1016/j.autrev.2021.102755⟩. ⟨hal-03163978⟩
515 Consultations
1027 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More